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Objectives: To assess the predictive value of in vitro drug susceptibility testing (DST) in slow-growing non-
tuberculous mycobacteria (NTM), knowledge on quantitative levels of drug susceptibility should be available.
The aim of this study was to investigate the suitability of the MGIT 960/TB eXiSTsystem for quantitative DSTof NTM.
Methods: We have assessed quantitative levels of drug susceptibility for clinical isolates of Mycobacterium avium,
Mycobacterium intracellulare and Mycobacterium kansasii by comparing radiometric Bactec 460TB-based DST with
non-radiometric DST using MGIT 960/TB eXiST.
Results: MGIT 960/TB eXiST gives results comparable to those of Bactec 460TB.
Conclusions: The MGIT 960/TB eXiST appears suitable for quantitative DST of NTM.
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Introduction
Antimicrobial therapy of infections with slow-growing non-
tuberculous mycobacteria (NTM) is hampered by the lack of
standardized procedures for drug susceptibility testing (DST).
The radiometric Bactec 460TB instrumentation (Becton
Dickinson Microbiology Systems, Sparks, MD, USA) has been
used in the past for susceptibility testing of slow-growing
NTM, mainly Mycobacterium avium complex (MAC) and Myco-
bacterium kansasii.1 – 4 In clinical laboratories the radiometric
system has largely been replaced, e.g. with the Mycobacterium
Growth Indicator Tube 960 system (MGIT 960, Becton Dickin-
son), not least because marketing of the Bactec 460TB instru-
mentation and associated consumables has been
terminated.5,6 A main advantage of the MGIT 960 platform is
the lack of radiochemistry, its full automation and its compat-
ibility with computerized expert systems for interpretation. The
aim of this study was to determine quantitative levels of drug
susceptibility for therapeutically relevant antibiotics using the
Bactec MGIT 960/EpiCenter v5.53 system (equipped with the
TB eXiST module) and a representative set of clinical isolates
of M. avium, Mycobacterium intracellulare and M. kansasii, and
to compare the results with those obtained by the radiometric
Bactec 460TB system.
Materials and methods
Organisms
Twenty-six clinical isolates (M. kansasii, n¼10; M. avium, n¼10;
M. intracellulare, n¼6) were investigated in this study; the strains origi-
nated from patient specimens submitted to the mycobacteriology labora-
tory of our institution (see Table S1, available as Supplementary data at
JAC Online). Mycobacterial isolates were identified by sequence analysis
of the 16S rRNA gene as described previously.7 Sequence analysis of
hsp65 was used to differentiate M. kansasii and Mycobacterium gastri.8
Antimicrobial agents
The antibiotics amikacin, clarithromycin, ethambutol, ofloxacin, rifabutin
and rifampicin (Sigma Aldrich Chemie GmbH, Buchs, Switzerland) were
selected based on guidelines for treatment of NTM.9 Ofloxacin was
chosen as the class representative for the newer quinolones. Antibiotic
concentrations chosen for the study are summarized in Table S2 (avail-
able as Supplementary data at JAC Online).
Susceptibility testing using Bactec 460TB and the MGIT
960 system with the EpiCenter TB eXiST software system
DST was performed as recommended by the manufacturer and test results
were interpreted as described previously.10 The terms susceptible (S),
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intermediate (I) and resistant (R) as used in this study describe in vitro
growth inhibition at a given drug concentration and are not to be confused
with predictability of clinical outcome. The I category indicates that the
studied drug concentration significantly (.99%), but not completely, inhi-
bits bacterial growth in vitro. An example is given in Figure S1 (available as
Supplementary data at JAC Online). In brief, positive MGIT vials were sub-
cultured for susceptibility testing as follows: (i) for subcultivations within
1 or 2 days after the MGIT 960 system recorded a positive growth signal,
bacterial suspensions with M. kansasii and M. intracellulare were diluted
1:5 and bacterial suspensions with M. avium were diluted 1:25 with
sterile 0.9% NaCl; and (ii) for subcultivations within 3–5 days after the
MGIT 960 system recorded a positive growth signal, bacterial suspensions
with M. kansasii and M. intracellulare were diluted 1:25 and bacterial sus-
pensions with M. avium were diluted 1:125 with sterile 0.9% NaCl. The
latter dilutions constituted the MGIT working suspensions. MGIT tubes sup-
plemented with 0.8 mL of enrichment (BACTEC MGIT 960 SIRE Sup-
plement; Becton Dickinson) were inoculated with 0.2 mL of drug solution
and 0.5 mL of the working suspension. For the drug-free growth control,
the working suspension was diluted 1:100 with sterile 0.9% NaCl and
0.5 mL of the diluted working suspension was inoculated (proportion
testing). The procedure for preparing the MGIT working suspensions was
determined empirically to generate a positive signal with the drug-free
growth control within 4–10 days following inoculation.
Statistical analysis
To assess the accuracy of quantitative DST, the results of MGIT 960
testing were compared with those of Bactec 460TB (Figure 1). Wilson’s
method was used to calculate the agreement of MGIT 960 and Bactec
460TB.11
Results
A total of 435 out of 520 data points showed complete agree-
ment. The overall agreement of MGIT 960 and Bactec 460TB
independent of antibiotic, drug concentration and species was
87.1% [95% confidence interval (CI) 80.2%–91.9%]. Disagree-
ments presented as minor errors exclusively. No major discre-
pancies (R versus S) were observed. Ofloxacin and amikacin
showed peaks of disagreements at concentrations of 10 mg/L
and 4 mg/L, respectively (Figure S2; available as Supplementary
data at JAC Online). The results are discussed in detail below.
Amikacin
Amikacin test results correlated well between MGIT 960 and
Bactec 460TB. A total of 104 data points were obtained, 91 of
which showed complete concordance. Thirteen data points of
10 isolates had minor discrepancies: (i) 3 isolates were R (MGIT
960) versus I (Bactec 460TB) at 1.0 mg/L, but resulted in S at
4 mg/L with both systems, indicating MICs between 1.0 mg/L
and 4 mg/L; and (ii) for 7 isolates minor discrepancies (R versus
I, I versus S) were observed at 4 mg/L (at a concentration of
10 mg/L these 7 isolates were found to be fully susceptible
with both test systems, indicating MICs for the isolates of
4–10 mg/L).
Clarithromycin
For clarithromycin, a total of 104 data points were obtained,
100 of which showed complete concordance. Four data
points of four isolates had minor discrepancies: two isolates
were S (MGIT 960) versus I (Bactec 460TB) at 4.0 mg/L; and a
further two isolates were S (MGIT 960) versus I (Bactec
460TB) at 16.0 mg/L. These four minor discrepancies were
resolved by congruent test results at the corresponding higher
drug concentration, indicating MICs for the corresponding iso-
lates close to 4 mg/L and 16 mg/L, respectively. Two isolates
of M. avium were resistant at all drug concentrations with
MGIT 960 and Bactec 460TB. Genetic sequencing was done
for one of the isolates and revealed a single point mutation
at 23S rRNA position 2058.12 Clinical macrolide resistance in
the MAC is almost exclusively associated with mutations in
23S rRNA, affecting nucleotide residues A2058 and A2059.12 –
15 These mutations confer high-level macrolide resistance, i.e.
MICs .64 mg/L.12 – 14,16 To further substantiate our findings
we studied a series of 14 M. avium and 4 M. intracellulare iso-
lates displaying macrolide resistance, with the resistance mech-
anism identified at the molecular level, i.e. mutation of 23S RNA
residue 2058 or 2059—including both clinical resistant strains
and laboratory mutants.12,13 The isolates unanimously tested
as resistant at all drug concentrations used in the MGIT 960
(MICs of clarithromycin .64 mg/L; see Table S3, available as
Supplementary data at JAC Online).
Ethambutol
For ethambutol, a total of 78 data points were obtained, 72 of
which showed complete concordance. Six data points of six iso-
lates had minor discrepancies: (i) one isolate was R (MGIT 960)
versus I (Bactec 460TB) at 5.0 mg/L, one isolate was I (MGIT
960) versus S (Bactec 460TB) at 5.0 mg/L and two isolates
were S (MGIT 960) versus I (Bactec 460TB) at 5.0 mg/L—all of
these isolates were S at 12.5 mg/L by both methods, indicating
that the MIC had to be close to 5 mg/L; and (ii) two isolates
were S (MGIT 960) versus I (Bactec 460TB) at 12.5 mg/L—both
resulted in S at 50 mg/L.
Ofloxacin
For ofloxacin, a total of 104 data points were obtained, 80 of
which showed complete concordance. Twenty-four data points
of 13 isolates had minor discrepancies: (i) 2 isolates were I
(MGIT 960) versus R (Bactec 460TB) at 2.0 mg/L, and S (MGIT
960) versus I (Bactec 460TB) at 10 mg/L, and 1 isolate was S
(MGIT 960) versus I (Bactec 460TB) at 2.0 mg/L and 10 mg/L—
all three isolates were S at 20 mg/L with both methods; (ii) 6
isolates were I (MGIT 960) versus R (Bactec 460TB) at 10.0 mg/L
[2 of the 6 isolates showed concordant results at 20 mg/L with
both systems (I and S, respectively) and 4 of the 6 isolates
were I (MGIT 960) versus R (Bactec 460TB) or S (MGIT 960)
versus I (Bactec 460TB) at 20 mg/L; 5 of the 6 isolates were S
at 50.0 mg/L with both test systems and 1 isolate resulted in S
(MGIT 960) versus I (Bactec 460TB) at 50.0 mg/L]; (iii) 3 isolates
were S (MGIT 960) versus I (Bactec 460TB) at 10.0 mg/L and
20.0 mg/L, and S at 50.0 mg/L with both methods; and (iv) 1
isolate was I (MGIT 960) versus R (Bactec 460TB) at 20.0 mg/L
and I at 50.0 mg/L with both methods.
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Rifabutin
For rifabutin, a total of 52 data points were obtained, 47 of which
showed complete concordance. Five data points of four isolates
had minor discrepancies: (i) two isolates were R (MGIT 960)
versus I (Bactec 460TB) at 0.1 mg/L [one of the two isolates
was S (MGIT 960, Bactec 460TB) at 1.0 mg/L and one isolate
was S (MGIT 960) versus I (Bactec 460TB) at 1.0 mg/L]; and
(ii) two isolates were S (MGIT 960) versus I (Bactec 460TB) at
1.0 mg/L. Comparing the three isolates, which were S and I for
rifabutin at 1.0 mg/L, with rifampicin testing results demon-
strated that rifampicin was R at 1.0 mg/L. With rifampicin at
10.0 mg/L, two out of three isolates were S (MGIT 960) versus I
(Bactec 460TB) and one isolate was I (MGIT 960) versus R
(Bactec 460TB). At 50.0 mg/L, two out of three isolates were S
Figure 1. Comparison of Bactec 460TB and MGIT 960 quantitative DST. Total number of NTM tested for amikacin, ethambutol, clarithromycin,
rifampicin, rifabutin and ofloxacin: n¼26 [M. kansasii (n¼10), M. avium (n¼10), M. intracellulare (n¼6)]; data separated according to species.
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(MGIT 960 and Bactec 460TB) and one isolate was S (MGIT 960)
versus I (Bactec 460TB).
Rifampicin
For rifampicin, a total of 78 data points were obtained, 63 of
which showed complete concordance. Fifteen data points of 13
isolates had minor discrepancies: (i) at 1.0 mg/L, 4 isolates
were R (MGIT 960) versus I (Bactec 460TB) and all isolates
resulted in S (MGIT 960, Bactec 460TB) at 10.0 mg/L; (ii) 2 iso-
lates were I (MGIT 960) versus R (Bactec 460TB) at 10.0 mg/L
[both resulted in S (MGIT 960) versus I (Bactec 460TB) at
50.0 mg/L]; (iii) 3 isolates were S (MGIT 960) versus I (Bactec
460TB) at 10.0 mg/L and S at 50 mg/L by both methods; and
(iv) 3 isolates were S (MGIT 960) versus I (Bactec 460TB) at
50.0 mg/L and 1 isolate was I (MGIT 960) versus R (Bactec
460TB) at 50.0 mg/L.
Discussion
There is an urgent need for standardized means and proper pro-
cedures for DST of NTM in the diagnostic laboratory. Only limited
information is available correlating in vitro susceptibility testing
results with clinical outcome.17,18 Drug susceptibility of NTM
may be quite heterogeneous, with remarkable interspecies
differences and intraspecies variability.3,4,19,20 As a result, the
definition of drug susceptibility by ‘critical concentration’
testing is barely possible. It is generally agreed that quantitative
DST may provide better correlation with clinical outcome and
allows monitoring of discrete changes in drug susceptibility
during treatment.21,22 Our results show high concordance for
Bactec 460TB and automated MGIT 960 readings compared
over a wide range of drug concentrations, and are in general
agreement with recent data comparing Bactec 460TB with
manual MGIT 960 readings.23,24 We observed only minor discre-
pancies, i.e. R versus I, I versus S (see Figure 1). If the true MIC
lies near the cut-off value for two adjacent interpretative cat-
egories, method-dependent fluctuations will randomly shift
interpretation to one or the other category, resulting in discre-
pancies. The closer the true MIC is to the cut-off for two adjacent
categories, the higher will be the frequency of corresponding dis-
crepancies.25 For example, our results show minor discrepancies
peaking at drug concentrations of 10 mg/L and 4 mg/L for oflox-
acin and amikacin, respectively (Figure S2). Inter-assay agree-
ment (reproducibility) of repeat testing ranged from 71% for
rifampicin to 100% for clarithromycin (Figure S3, available as
Supplementary data at JAC Online), and only minor disagree-
ments were recorded.
With the exception of DST for clarithromycin the clinical rel-
evance of in vitro DST is not well established for slow-growing
NTM, in part because of the lack of standardized procedures for
in vitro susceptibility testing and, until recently, the lack of corre-
lation with clinical efficacy and outcome. As a result, the current
recommendations for NTM DST only include clarithromycin.26 In
contrast to M. tuberculosis, clinical isolates of slow-growing
NTM with any defined resistance phenotype other than clarithro-
mycin and associated with a well-characterized molecular
genetic alteration are largely lacking. Therefore, with the excep-
tion of clarithromycin, we were unable to study clinical NTM
strains with acquired resistance to any of the other drugs
investigated in this study, i.e. amikacin, ethambutol, ofloxacin,
rifampicin or rifabutin. To the best of our knowledge, correspond-
ing series of well-characterized drug-resistant NTM clinical iso-
lates have not been described in the literature. While this is a
significant limitation and shortcoming of the study, our data
are relevant, as they provide the information necessary to recog-
nize wild-type susceptibility and any possible change thereof. In
our study we included a significant number of well-defined
macrolide-resistant MAC strains to validate MGIT 960/EpiCenter
TB eXiST for recognition of macrolide resistance.
Future studies will be necessary to investigate the accuracy of
the MGIT 960 system for recognition of drug resistance other
than clarithromycin. The discontinuation of the Bactec 460TB
platform makes the development of alternative testing pro-
cedures urgent. At the very least, our study demonstrates that
MGIT 960 DST gives results comparable to those of Bactec
460TB. Several features of the MGIT 960/EpiCenter platform
offer significant advantages compared with the Bactec 460TB
system, e.g. non-radioactive growth detection, full automation,
software-supported data interpretation and ease of standardiz-
ation. The procedure investigated in this study is a first step in
the establishment of standardized, rapid and reliable techniques
for quantitative DST of NTM. Additional studies including
drug-resistant clinical isolates are warranted to assess the accu-
racy of the MGIT 960 system for recognition of drug resistance in
NTM.
Acknowledgements
Part of this work was presented at the Thirty-first Annual Congress of the
European Society for Mycobacteriology, Bled, Slovenia, 2010 (Poster PP-45).
We thank Guido Bloemberg for critical reading of the manuscript and
Malgorzata Roos for support with biostatistics.
Funding
This study was supported in part by the University of Zurich and by grants
from the Bundesamt fu¨r Gesundheit (Bern, Switzerland).
Transparency declarations
E. C. B. has a consultancy agreement with Becton-Dickinson. All other
authors: none to declare.
Supplementary data
Tables S1–S3 and Figures S1–S3 are available as Supplementary data at
JAC Online (http://jac.oxfordjournals.org/).
References
1 Alcaide F, Calatayud L, Santin M et al. Comparative in vitro activities of
linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and
four conventional antimycobacterial drugs against Mycobacterium
kansasii. Antimicrob Agents Chemother 2004; 48: 4562–5.
2 National Committee for Clinical Laboratory Standards. Susceptibility
Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes:
Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
Quantitative drug susceptibility testing of non-tuberculous mycobacteria
157
JAC
3 Siddiqi SH, Heifets LB, Cynamon MH et al. Rapid broth macrodilution
method for determination of MICs for Mycobacterium avium isolates. J
Clin Microbiol 1993; 31: 2332–8.
4 Woods GL, Williams-Bouyer N, Wallace RJ Jr et al. Multisite
reproducibility of results obtained by two broth dilution methods for
susceptibility testing of Mycobacterium avium complex. J Clin Microbiol
2003; 41: 627–31.
5 Pfyffer GE, Welscher HM, Kissling P et al. Comparison of the
Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid
culture for recovery of acid-fast bacilli. J Clin Microbiol 1997; 35: 364–8.
6 Tortoli E, Benedetti M, Fontanelli A et al. Evaluation of automated
BACTEC MGIT 960 system for testing susceptibility of Mycobacterium
tuberculosis to four major antituberculous drugs: comparison with the
radiometric BACTEC 460TB method and the agar plate method of
proportion. J Clin Microbiol 2002; 40: 607–10.
7 Rogall T, Flohr T, Bottger EC. Differentiation of Mycobacterium species by
direct sequencing of amplified DNA. J Gen Microbiol 1990; 136: 1915–20.
8 Telenti A, Marchesi F, Balz M et al. Rapid identification of mycobacteria
to the species level by polymerase chain reaction and restriction enzyme
analysis. J Clin Microbiol 1993; 31: 175–8.
9 Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due
to Mycobacterium avium complex. Semin Respir Crit Care Med 2008; 29:
569–76.
10 Springer B, Lucke K, Calligaris-Maibach R et al. Quantitative drug
susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960
and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773–80.
11 Altman DG, Newcombe RG. Proportions and their differences and
diagnostic tests. In: Altman DG, Machin D, Bryant TN et al., eds. Statistics
with Confidence. 2nd edn. London: BMJ Books, 2000; 46–8, 106–7.
12 Meier A, Kirschner P, Springer B et al. Identification of mutations in
23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.
Antimicrob Agents Chemother 1994; 38: 381–4.
13 Meier A, Heifets L, Wallace RJ Jr et al. Molecular mechanisms of
clarithromycin resistance in Mycobacterium avium: observation of
multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996;
174: 354–60.
14 Nash KA, Inderlied CB. Genetic basis of macrolide resistance in
Mycobacterium avium isolated from patients with disseminated
disease. Antimicrob Agents Chemother 1995; 39: 2625–30.
15 Nash KA, Inderlied CB. Rapid detection of mutations associated with
macrolide resistance in Mycobacterium avium complex. Antimicrob
Agents Chemother 1996; 40: 1748–50.
16 Pfister P, Jenni S, Poehlsgaard J et al. The structural basis of
macrolide-ribosome binding assessed using mutagenesis of 23S rRNA
positions 2058 and 2059. J Mol Biol 2004; 342: 1569–81.
17 Shafran SD, Talbot JA, Chomyc S et al. Does in vitro susceptibility to
rifabutin and ethambutol predict the response to treatment of
Mycobacterium avium complex bacteremia with rifabutin, ethambutol,
and clarithromycin? Canadian HIV Trials Network Protocol 010 Study
Group. Clin Infect Dis 1998; 27: 1401–5.
18 Sison JP, Yao Y, Kemper CA et al. Treatment of Mycobacterium avium
complex infection: do the results of in vitro susceptibility tests predict
therapeutic outcome in humans? J Infect Dis 1996; 173: 677–83.
19 van Ingen J, van der Laan T, Dekhuijzen R et al. In vitro drug
susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates
of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35:
169–73.
20 Heifets L. Susceptibility testing of Mycobacterium avium complex
isolates. Antimicrob Agents Chemother 1996; 40: 1759–67.
21 Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:
367–416.
22 Heifets L. Qualitative and quantitative drug-susceptibility tests in
mycobacteriology. Am Rev Respir Dis 1988; 137: 1217–22.
23 Krishnan MY, Manning EJ, Collins MT. Comparison of three methods
for susceptibility testing of Mycobacterium avium subsp.
paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother
2009; 64: 310–6.
24 Piersimoni C, Nista D, Bornigia S et al. Evaluation of a new method for
rapid drug susceptibility testing of Mycobacterium avium complex isolates
by using the mycobacteria growth indicator tube. J Clin Microbiol 1998;
36: 64–7.
25 Altman DG. Inter rater agreement. In: Practical Statistics for Medical
Research. London: Chapman and Hall, 1991; 403–9.
26 Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin
Infect Dis 2010; 23: 185–90.
Lucke et al.
158
